Haemonetics 4th Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Haemonetics (HAE) PT Lowered to $86 at Needham & Company
May 13, 2021 1:03 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $86.00 (from $108.00) while maintaining a Buy rating.
The analyst commented, "HAE's F4Q21 revenue beat and EPS missed consensus. HAE's organic growth slowed to (13.7%) in F4Q21 vs. (5.7%)... More
Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
May 13, 2021 6:07 AM EDTHaemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
